Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors.
Kassem S FarajMary OerlineSamuel R KaufmanChristopher DallArnav SrivastavaMegan E V CaramVahakn B ShahinianBrent K HollenbeckPublished in: Journal of the National Cancer Institute (2024)
Men with advanced prostate cancer initiating an androgen biosynthesis inhibitor for the first time more commonly had cardiometabolic events than those started on androgen receptor inhibitors. Neurocognitive events and fractures did not differ by drug class.